PRKD3 protein kinase D3
ENSG00000115825 · protein coding · Open Targets profile
Converts transient diacylglycerol (DAG) signals into prolonged physiological effects, downstream of PKC. Involved in resistance to oxidative stress (By similarity). .
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Approved Drug, High-Quality Ligand, Druggable Family
- Antibody
- GO CC high conf, Human Protein Atlas loc
- PROTAC
- Database Ubiquitination, Small Molecule Binder
gnomAD loss of function constraint: o/e 0.4739600121974945 (upper bound 0.6044099926948547). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 24 registry trials, updated in the last three years, of the most advanced drugs against PRKD3 (midostaurin, sotrastaurin, UCN-01), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Christian RECHER+33 5 31 15 63 55 · 1 of 1 trials Phase 2+
- Christoph RölligTechnische Universität Dresden, Medical Faculty Carl Gustav Carus · 1 of 1 trials Phase 2+
- Christoph RummeltUniversity Hospital Freiburg · 1 of 1 trials Phase 2+
- Gerwin HulsUMCG / HOVON · 1 of 1 trials Phase 2+
- Ido Didi FabianSheba Medical Center · 1 of 1 trials Phase 2+
- Laura C MichaelisSWOG Cancer Research Network · 1 of 1 trials Phase 2+
- M. RaaijmakersErasmus MC / HOVON · 1 of 1 trials Phase 2+Ph3NCT04027309 · A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapybrief
- Meagan JacobyWashington University School of Medicine · 1 of 1 trials Phase 2+
- Richard M. StoneDana-Farber Cancer Institute · 1 of 1 trials Phase 2+
- Selena LugerUniversity of Pennsylvania · 1 of 1 trials Phase 2+
- Tapan M KadiaM.D. Anderson Cancer Center · 1 of 1 trials Phase 2+
- Vijaya R BhattUniversity of Nebraska · 1 of 1 trials Phase 2+
- Rafael BejarAptose Biosciences Inc. · 0 of 1 trials Phase 2+
Registry trials of midostaurin, sotrastaurin, UCN-01 updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 16 of 22 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 2 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
21 trials of drugs against PRKD3 were stopped early; 4 give no reason
Terminated, withdrawn and suspended interventional trials of midostaurin, sotrastaurin, UCN-01, GSK-690693, CEP-2563, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 21 most recent of 21.
- terminated · 2025-03-07 · Aptose Biosciences Inc. · matched by the registry's drug synonyms“Change in corporate strategy”
- terminated · 2025-02-25 · Niguarda Hospital · Midostaurin“didn't reach the primary endpoint”
- withdrawn · 2024-10-01 · Guenther Koehne · Midostaurin“Could not accrue”
- terminated · 2022-10-06 · Insel Gruppe AG, University Hospital Bern · Midostaurin“Insufficient recruitment”
- withdrawn · 2022-05-25 · University Hospital Heidelberg · matched by the registry's drug synonyms“Study turned out no longer feasible”
- terminated · 2022-01-21 · University of Jena · Midostaurin“Insufficient Recruitment”
- terminated · 2020-12-19 · Novartis Pharmaceuticals · matched by the registry's drug synonyms“Study terminated due to enrolment challenges and availability of other options for DLBCL patients. The termination is not a consequence of any safety concern.”
- terminated · 2020-12-17 · Novartis Pharmaceuticals · matched by the registry's drug synonymsNo reason given
- terminated · 2020-09-16 · Array Biopharma, now a wholly owned subsidiary of Pfizer · matched by the registry's drug synonyms“The trial was terminated for scientific reasons.”
- withdrawn · 2020-01-09 · Novartis Pharmaceuticals · midostaurin“It was determined that the study design may not be optimal given the changing AML treatment landscape.”
- terminated · 2019-08-07 · Mayo Clinic · MidostaurinNo reason given
- withdrawn · 2018-10-22 · University of Florida · Midostaurin“Insufficient funding”
- terminated · 2018-09-27 · David Iberri · Midostaurin“Accrual factor”
- withdrawn · 2018-05-04 · Stanford University · Midostaurin“Logistical and administrative issues”
- terminated · 2017-05-15 · National Cancer Institute (NCI) · UCN-01 (7-hydroxystaurosporine)“IND was withdrawn by CTEP due to low accrual and cost of maintaining the IND.”
- withdrawn · 2017-04-05 · James Blachly · sotrastaurin acetate“Decision made by the Principal Investigator”
- terminated · 2017-01-18 · GlaxoSmithKline · matched by the registry's drug synonymsNo reason given
- terminated · 2015-12-22 · Novartis Pharmaceuticals · midostaurin“Despite considerable efforts to boost recruitment during the final year of the study, no new patients were enrolled.”
- withdrawn · 2015-04-17 · GlaxoSmithKline · matched by the registry's drug synonyms“Study Cancelled before enrollment”
- terminated · 2015-03-02 · National Cancer Institute (NCI) · matched by the registry's drug synonyms“Early termination for discouraging results”
- terminated · 2013-07-09 · National Cancer Institute (NCI) · matched by the registry's drug synonymsNo reason given
Paediatric incentives and obligations for PRKD3's drugs
For midostaurin, sotrastaurin, UCN-01, GSK-690693, CEP-2563: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · PRKD3 is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMEA-000780-PIP01-09-M08 (Midostaurin, Treatment of acute myeloid leukaemia;Treatment of malignant mastocytosis;Treatment of mast cell leukaemia): PM: decision on the application for modification of an agreed PIP, 16 Aug 2024; EMEA-000093-PIP02-10 (sotrastaurin acetate, Prevention of rejection of transplanted kidney): W: decision granting a waiver in all age groups for all conditions or indications, 26 Jan 2011; EMEA-000093-PIP01-07-M01 (sotrastaurin acetate, Treatment of chronic plaque psoriasis): PM: decision on the application for modification of an agreed PIP, 4 Jul 2011Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: yes · EU/3/10/765 positive 4 Aug 2010: Treatment of mastocytosis; EU/3/04/214 positive 29 Jul 2004: Treatment of acute myeloid leukaemiaRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Rydapt: authorised since 18 Sept 2017, orphan medicineRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA EPAR Rydapt, 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of midostaurin, sotrastaurin, ucn-01, gsk-690693, cep-2563Rule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: yes · 6 interventional studies of midostaurin, sotrastaurin, ucn-01, gsk-690693, cep-2563 include patients under 18; 1 is recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 5 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.